Literature DB >> 10435767

DEPRES II (Depression Research in European Society II): a patient survey of the symptoms, disability and current management of depression in the community. DEPRES Steering Committee.

A Tylee1, M Gastpar, J P Lépine, J Mendlewicz.   

Abstract

The first pan-European survey of depression in the community (DEPRES I) demonstrated that 17% of the general population suffer from depression (major depression, minor depression, or depressive symptoms). This article describes findings from a second phase of DEPRES (DEPRES II), in which detailed interviews based on a semi-structured questionnaire (78 questions) were conducted with 1884 DEPRES I participants who had suffered from depression and who consulted a healthcare professional about their symptoms during the previous 6 months. The mean time from onset of depression was 45 months, and the most commonly experienced symptoms during the latest period were low mood (76%), tiredness (73%) and sleep problems (63%). During the previous 6 months, respondents had been unable to undertake normal activities because of their depression for a mean of 30 days, and a mean of 20 days of work had been lost to depression by those in paid employment. Approximately one-third of respondents (30%) had received an antidepressant during the latest period of depression. Significantly more respondents given a selective serotonin reputake inhibitor found that their treatment made them feel more like their normal self than those given a tricyclic antidepressant, and fewer reported treatment-related concentration lapses, weight problems, and heavy-headedness (all P < 0.05). Approximately two-thirds of respondents (70%) had received no antidepressant therapy during the latest period of depression, and prescription of benzodiazepines alone, which are not effective against depression, was widespread (17%). There is a need for education of healthcare professionals to encourage appropriate treatment of depression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10435767     DOI: 10.1097/00004850-199905002-00001

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  45 in total

1.  Why treat depression differently from other medical problems?

Authors:  Pierre Blier
Journal:  J Psychiatry Neurosci       Date:  2002-07       Impact factor: 6.186

2.  Workplace stress and prescription of antidepressant medications: a prospective study on a sample of Italian workers.

Authors:  Angelo d'Errico; Mario Cardano; Tania Landriscina; Chiara Marinacci; Sherri Pasian; Alessio Petrelli; Giuseppe Costa
Journal:  Int Arch Occup Environ Health       Date:  2010-10-16       Impact factor: 3.015

3.  Sleepiness Versus Sleeplessness: Shift Work and Sleep Disorders in the Primary Care Setting.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2004

Review 4.  Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits.

Authors:  J D Salamone; M Correa; A Farrar; S M Mingote
Journal:  Psychopharmacology (Berl)       Date:  2007-01-16       Impact factor: 4.530

5.  Patterns of morning and evening fatigue among adults with HIV/AIDS.

Authors:  Anners Lerdal; Caryl L Gay; Bradley E Aouizerat; Carmen J Portillo; Kathryn A Lee
Journal:  J Clin Nurs       Date:  2011-08       Impact factor: 3.036

6.  Forebrain circuitry involved in effort-related choice: Injections of the GABAA agonist muscimol into ventral pallidum alter response allocation in food-seeking behavior.

Authors:  A M Farrar; L Font; M Pereira; S Mingote; J G Bunce; J J Chrobak; J D Salamone
Journal:  Neuroscience       Date:  2008-01-01       Impact factor: 3.590

7.  Differential actions of adenosine A1 and A2A antagonists on the effort-related effects of dopamine D2 antagonism.

Authors:  John D Salamone; Andrew M Farrar; Laura Font; Vatsal Patel; Devra E Schlar; Eric J Nunes; Lyndsey E Collins; Thomas N Sager
Journal:  Behav Brain Res       Date:  2009-03-03       Impact factor: 3.332

8.  The adenosine A2A antagonist MSX-3 reverses the effort-related effects of dopamine blockade: differential interaction with D1 and D2 family antagonists.

Authors:  Lila T Worden; Mona Shahriari; Andrew M Farrar; Kelly S Sink; Jörg Hockemeyer; Christa E Müller; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2008-12-02       Impact factor: 4.530

9.  Adenosine A(2A) receptor antagonism reverses the effects of dopamine receptor antagonism on instrumental output and effort-related choice in the rat: implications for studies of psychomotor slowing.

Authors:  Andrew M Farrar; Mariana Pereira; Francisco Velasco; Jörg Hockemeyer; Christa E Müller; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2006-10-27       Impact factor: 4.530

10.  Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75-225 mg/day in patients with recurrent major depression: a secondary analysis of data from the PREVENT study.

Authors:  Susan G Kornstein; James H Kocsis; Saeeduddin Ahmed; Michael Thase; Edward S Friedman; Boadie W Dunlop; Bing Yan; Ron Pedersen; Philip T Ninan; Thomas Li; Martin Keller
Journal:  Int Clin Psychopharmacol       Date:  2008-11       Impact factor: 1.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.